Sudarshan Pharma Industries Complete Financial Statements

In FY2025, Sudarshan Pharma Industries (SUDARSHAN) reported revenue ₹171 Cr, net profit ₹4 Cr and EPS ₹0.16, with a net profit margin of 2.3% and ROE of 3.0%. Full financial statements from FY2020 to FY2025 (6 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Sudarshan Pharma Industries stock price NSE .

6 Years of Data
2025 - 2020

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 2.34% 2025 data
EBITDA Margin 6.43% 2025 data
Operating Margin 5.00% 2025 data
Return on Assets 1.00% 2025 data
Return on Equity 3.03% 2025 data

Balance Sheet Ratios

Current Ratio 30.45 2025 data
Equity Ratio 32.84% 2025 data
Asset Turnover 0.43 2025 data

SUDARSHAN Revenue, Net Profit & EBITDA — Year-on-Year Growth

SUDARSHAN YoY (Sept 2024 vs Sept 2025) — revenue +32.6%, net profit -33.3%, EBITDA -8.3%, expenses +36.8%.

Revenue Growth
+32.6%
Year-over-Year
Net Profit Growth
-33.3%
Year-over-Year
EBITDA Growth
-8.3%
Year-over-Year
Expense Growth
+36.8%
Year-over-Year
Assets Growth
+42.0%
Year-over-Year
Equity Growth
+17.9%
Year-over-Year
Operating Cash Flow Growth
+337.5%
Year-over-Year
Investing Cash Flow Growth
-185.7%
Year-over-Year
Financing Cash Flow Growth
-16.7%
Year-over-Year

SUDARSHAN Income Statement — Revenue, EBITDA & Net Profit

Sudarshan Pharma Industries revenue ₹171 Cr, EBITDA ₹11 Cr, net profit ₹4 Cr, EPS ₹0.16 (2025) — net profit margin 2.3%. Explore SUDARSHAN investment value to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Mar 2024 Jun 2024 Dec 2024
Revenue 171 162 147 170 129 232 100 116
Expenses 160 147 134 157 117 217 97 108
EBITDA 11 15 12 12 12 15 3 9
Operating Profit Margin % 5.00% 9.00% 8.00% 6.00% 9.00% 6.00% 2.00% 7.00%
Depreciation 1 1 1 1 1 1 1 1
Interest 6 4 6 6 4 6 4 4
Profit Before Tax 4 10 5 5 8 9 -2 4
Tax 0 3 1 1 2 2 0 1
Net Profit 4 7 4 4 6 7 -1 3
Earnings Per Share (₹) 0.16 0.31 0.16 0.18 0.24 0.27 -0.05 0.12

SUDARSHAN Balance Sheet — Assets, Liabilities & Shareholders' Equity

SUDARSHAN total assets ₹402 Cr, total equity ₹132 Cr, total liabilities ₹ Cr (2025) — ROE 3.0%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020
ASSETS
Total Assets 402 283 233 138 99 58
Current Assets 335 237 199 130 88 47
Fixed Assets 24 26 20 7 6 6
Capital Work in Progress 6 2 0 1 0 0
Investments 2 2 0 0 0 0
Other Assets 371 254 213 131 93 53
LIABILITIES
Total Liabilities
Current Liabilities 11 11 13 5 6 7
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 132 112 101 30 23 20
Share Capital 24 24 24 10 10 10
Reserves & Surplus 104 88 77 20 13 10

SUDARSHAN Cash Flow Statement — Operating, Investing & Financing

Sudarshan Pharma Industries operating cash flow ₹35 Cr, investing ₹-20 Cr, financing ₹-14 Cr, net cash flow ₹0 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020
Operating Activities 35 8 -29 -4 3 1
Investing Activities -20 -7 -26 -2 -1 -3
Financing Activities -14 -12 66 4 -2 0
Net Cash Flow 0 -12 12 -1 0 -2